SomaLogic to provide 210 million protein measurements to EPIC researchers to better understand and predict cancer development
SomaLogic will use its industry leading SomaScan Assay to analyze 210 million protein measurements from 30,000 samples spanning 15 years of clinical interactions to help researchers understand and predict cancer development.
- SomaLogic will use its industry leading SomaScan Assay to analyze 210 million protein measurements from 30,000 samples spanning 15 years of clinical interactions to help researchers understand and predict cancer development.
- The collaboration between SomaLogic and EPIC aims to develop potentially predictive protein markers in cancer and other diseases.
- This may lead to fundamental discoveries enhancing clinical understanding of cancer and its treatment, or to the development of screening and diagnostic tools to improve outcomes.
- Over the EPIC study period of 1992 to 2015, more than 67,000 participants were diagnosed with cancer.